Tumor necrosis factor-related apoptosis-inducing ligand pathway (TRAIL pathway)

The tumor necrosis factor-related apoptosis-inducing ligand pathway (TRAIL pathway) refers to a signaling cascade initiated by the TRAIL ligand, a member of the TNF cytokine superfamily, primarily involved in the induction of apoptosis especially in malignant or transformed cells[1][3][5][8]. TRAIL is a homotrimeric type 2 transmembrane protein encoded by the TNFSF10 gene[2][6]. It binds to its cognate death receptors—DR4 (TRAIL-R1) and DR5 (TRAIL-R2)—on the cell surface, resulting in the recruitment and activation of the death-inducing signaling complex (DISC)[1][2][4]. This leads to caspase-8/-10 activation and apoptotic cell death, with selectivity for tumor cells and minimal effect on normal cells[3][8]. TRAIL can also be found as a soluble ligand cleaved from the membrane, but only membrane-bound TRAIL robustly induces apoptotic signaling[2][3]. In clinical oncology, the TRAIL pathway is actively studied as a therapeutic target, with recombinant TRAIL, death receptor agonists, and TRAIL-inducing agents under investigation to harness its tumor-selective apoptosis[1][8]. Challenges include tumor resistance mechanisms and drug delivery, but the pathway remains a key focus for advancing targeted cancer therapies[3][8].

Other names

Tumor necrosis factor-related apoptosis-inducing ligand pathwayTRAIL pathwayTNF-related apoptosis-inducing ligand pathwayApo2L/TRAIL pathway

Agonism at TRAIL death receptors (DR4/TRAIL-R1, DR5/TRAIL-R2) to induce apoptosis via DISC and caspase activation; Upregulation of TRAIL expression to enhance endogenous apoptosis signaling; Sensitization of tumor cells to apoptosis (combination with chemotherapeutics to overcome resistance)